Biotech Showcase™ provides private and public life science companies the opportunity to present to an audience of investors and business development executives during the course of the industry's largest annual healthcare investor conference.
Now in its fourth year, Biotech Showcase 2012 is expected to attract upwards of 1,500 attendees. The program includes lunch plenary sessions featuring top industry leaders and innovators speaking on industry- and time-relevant topics, as well as presentations from both private and public companies.
ImmunoCellular Therapeutics (OTC BB: IMUC) receives Notice of Allowance of Cancer Stem Cell Targeting Patent
OTC BB: IMUC received allowance of US patent claims
OTC BB: IMUC received related notice to its method of treating glioblastoma multiforme (GBM) in a patient by targeting cancer stem cells (CSC) from the USPTO.
- The patent titled “Cancer Stem Cell Antigen Vaccines and Methods,” which covers various methods of using dendritic cells combined with antigens derived from glioblastoma CSCs for the treatment of GBM has been allowed.
The Bottom Line: This notice of allowance for this patent provides support for stronger intellectual property protection targeting cancer stem cells.
- ImmunoCellular Therapeutics (OTC BB: IMUC) is UP +$0.08 <+4.88%> to $1.72 in early trading …
Register here to be notified of future Biotech Showcase 2012 articles.
